Literature DB >> 14514

Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine.

D L Garver, H Dekirmenjian, J M Davis, R Casper, S Ericksen.   

Abstract

The authors studied neuroleptic concentration-therapeutic response curves for butaperazine (BPZ), a piperazine phenothiazine, in 10 schizophrenic patients during the first 12 days of treatment. BPZ bound to red blood cells (RBC) was more strongly correlated with therapeutic response than was plasma BPZ. RBC BPZ concentrations could be used to define a "therapeutic window", an optimun concentration for therapeutic response, above and below which favorable response diminishes. The authors emphasize the preliminary nature of the data but suggest that levels of RBC-bound neuroleptic may provide an important guide for dosage regulation in schizophrenic patients.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 14514     DOI: 10.1176/ajp.134.3.304

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  10 in total

1.  Serum neuroleptic concentrations and clinical response: a radioreceptor assay investigation of acutely psychotic patients.

Authors:  L T Kucharski; P Alexander; L Tune; J Coyle
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

2.  Neuroleptic blood levels and therapeutic effect.

Authors:  B M Cohen; J F Lipinski; H G Pope; P Q Harris; R I Altesman
Journal:  Psychopharmacology (Berl)       Date:  1980       Impact factor: 4.530

3.  Serum and CSF levels of haloperidol by radioimmunoassay and radioreceptor assay during high-dose therapy of resistant schizophrenic patients.

Authors:  R Rimón; I Averbuch; P Rozick; L Fijman-Danilovich; T Kara; H Dasberg; R P Ebstein; R H Belmaker
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

4.  Relationship of butaperazine blood levels to plasma prolactin in chronic schizophrenic patients.

Authors:  R C Smith; C A Tamminga; J W Crayton; H Dekirmenjian; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1979       Impact factor: 4.530

5.  Comparison of plasma, venous and capillary blood levels of piperaquine in patients with uncomplicated falciparum malaria.

Authors:  Elizabeth A Ashley; Kasia Stepniewska; Niklas Lindegardh; Anna Annerberg; Joel Tarning; Rose McGready; Lucy Phaiphun; Pratap Singhasivanon; Nicholas J White; François Nosten
Journal:  Eur J Clin Pharmacol       Date:  2010-03-19       Impact factor: 2.953

6.  Red blood cell and plasma levels of thioridazine and mesoridazine in schizophrenic patients.

Authors:  A Shvartsburd; V Nwokeafor; R C Smith
Journal:  Psychopharmacology (Berl)       Date:  1984       Impact factor: 4.530

Review 7.  Plasma level monitoring of antipsychotic drugs. Clinical utility.

Authors:  S G Dahl
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

8.  Comparative efficacy of red cell and plasma haloperidol as predictors of clinical response in schizophrenia.

Authors:  R C Smith; R Baumgartner; A Shvartsburd; G K Ravichandran; G Vroulis; M Mauldin
Journal:  Psychopharmacology (Berl)       Date:  1985       Impact factor: 4.530

9.  Mechanisms of action of antipsychotic drugs of different classes, refractoriness to therapeutic effects of classical neuroleptics, and individual variation in sensitivity to their actions: Part II.

Authors:  R Miller
Journal:  Curr Neuropharmacol       Date:  2009-12       Impact factor: 7.363

10.  Fluphenazine pharmacokinetics and therapeutic response.

Authors:  M W Dysken; J I Javaid; S S Chang; C Schaffer; A Shahid; J M Davis
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.